The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Seed Amplification Assay Program, 2021Development of a Simplified, Rapid Method for Measuring Alpha-synuclein in Clinical Samples
Study Rationale: Alpha-synuclein aggregates are considered to be an excellent biomarker for the diagnosis of Parkinson’s disease (PD). The challenge is to optimize the tests currently used to detect...
-
Alpha-synuclein Seed Amplification Assay Program, 2021Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles
Study Rationale: The pathological changes observed in the brain tissue of people with Parkinson’s disease (PD) compared to healthy individuals motivated researchers to explore alpha-synuclein as a...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Development of a Reliable Diagnostic Test for Parkinson’s Disease Using Patient Blood Samples
Study Rationale: Although diagnosis of Parkinson’s disease (PD) is crucial for the success of treatment, especially in the early stages, there are still no biomarkers available for use as a reliable...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease
Study Rationale: A hallmark characteristic of Parkinson’s disease (PD) is the accumulation of alpha-synuclein, a small lipid-binding protein involved in transporting lipids and proteins throughout the...
-
Therapeutic Pipeline Program, 2021Identifying Small Molecule Binders of the LRRK2 WD Domain
Study Rationale:
Individuals with genetic variations or mutations in a gene called LRRK2 are at increased risk of developing Parkinson’s disease (PD). Because these alterations enhance the activity of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.